PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Korea Post Marketing Surveillance (PMS) Study of Vizimpro

Conditions: Lung Neoplasms

Interventions: Drug: Vizimpro

First Posted Date: 2021-01-22

Last Posted Date: 2024-11-04

Lead Sponsor: Pfizer

Target Recruit Count: 187

Registration Number: NCT04721106

Locations: 🇰🇷
Pfizer, Seoul, Korea, Republic of

Oral Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis in Adult Japanese Participants (ELEVATE UC 40 JAPAN)

Phase 3

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Etrasimod

First Posted Date: 2021-01-13

Last Posted Date: 2023-10-16

Lead Sponsor: Pfizer

Target Recruit Count: 42

Registration Number: NCT04706793

Locations: 🇯🇵
Kojunkai Daido Clinic, Nagoya-shi, Aichi-ken, Japan
🇯🇵
Ishii Eye Clinic, Nagareyama-shi, Chiba, Japan
🇯🇵
Fukuoka University Hospital, Fukuoka-shi, Fukuoka, Japan

and more 35 locations

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: PF-06882961 (Cohort 3)
Drug: PF-06882961 (Cohorts 1 and 2)
Drug: Placebo (Cohorts 1 and 2)
Drug: Placebo (Cohort 3)

First Posted Date: 2021-01-13

Last Posted Date: 2024-11-05

Lead Sponsor: Pfizer

Target Recruit Count: 628

Registration Number: NCT04707313

Locations: 🇺🇸
PMG Research, Inc. d/b/a PMG Research of Knoxville, Knoxville, Tennessee, United States
🇨🇦
Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada
🇨🇦
Aggarwal and Associates Limited, Brampton, Ontario, Canada

and more 37 locations

Study of the Efficacy and Safety of Somatropin in Japanese Participants With PWS

Phase 3

Completed

Conditions: Prader-Willi Syndrome

Interventions: Biological: somatropin - GH naïve pediatric cohort
Biological: somatropin - GH treated cohort
Biological: somatropin - adult cohort

First Posted Date: 2021-01-06

Last Posted Date: 2024-06-05

Lead Sponsor: Pfizer

Target Recruit Count: 33

Registration Number: NCT04697381

Locations: 🇯🇵
Kanagawa Children's Medical Center, Yokohama, Kanagawa, Japan
🇯🇵
Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan
🇯🇵
Osaka Women's and Children's Hospital, Izumi, Osaka, Japan

and more 2 locations

A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

Phase 2

Completed

Conditions: Eosinophilic Esophagitis

Interventions: Drug: Etrasimod
Drug: Placebo

First Posted Date: 2020-12-24

Last Posted Date: 2024-05-06

Lead Sponsor: Pfizer

Target Recruit Count: 108

Registration Number: NCT04682639

Locations: 🇺🇸
Mile Square Surgery Center, Fountain Valley, California, United States
🇺🇸
Bay Area Chest Physicians, P.A., - Pulmonary Function Test, Clearwater, Florida, United States
🇺🇸
Dothan Eyecare - Dr. Brent McKinley (OCT Procedure Only), Dothan, Alabama, United States

and more 249 locations

To Examine the Effects of Axitinib Dose Reduction and Interruption for Adverse Event Management Among Patients Receiving Axitinib in for the Treatment of Advanced Renal Cell Carcinoma

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2020-12-24

Last Posted Date: 2025-01-03

Lead Sponsor: Pfizer

Target Recruit Count: 481

Registration Number: NCT04682587

Locations: 🇺🇸
Pfizer, New York, New York, United States

Effectiveness And Safety Of Oral Anticoagulants Among Obese Patients With Non-Valvular A-Fib In VA Patients With Medicare

Completed

Conditions: Atrial Fibrillation
Anticoagulants
Obesity

Interventions: Drug: Apixaban

First Posted Date: 2020-12-23

Last Posted Date: 2023-05-22

Lead Sponsor: Pfizer

Target Recruit Count: 107383

Registration Number: NCT04681482

Locations: 🇺🇸
Pfizer, New York, New York, United States

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors
Breast Cancer
Pancreatic Cancer
Solid Tumors
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
NSCLC

Interventions: Drug: TALZENNA capsule
Drug: Talazoparib soft gel capsule

First Posted Date: 2020-12-17

Last Posted Date: 2022-12-07

Lead Sponsor: Pfizer

Target Recruit Count: 73

Registration Number: NCT04672460

Locations: 🇺🇸
Mary Crowley Cancer Research - Medical City Hospital, Dallas, Texas, United States
🇺🇸
West Chester Hospital, West Chester, Ohio, United States
🇺🇸
California Cancer Associates for Research and Excellence, Inc (cCARE), San Marcos, California, United States

and more 25 locations

A Study to Understand the Treatment Patterns and Patients and Their Clinical Outcomes Who Are Taking Palbociclib in a Real Life Setting in Israel.

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: palbociclib

First Posted Date: 2020-12-17

Last Posted Date: 2023-10-30

Lead Sponsor: Pfizer

Target Recruit Count: 559

Registration Number: NCT04671615

Locations: 🇮🇱
Pfizer Pharmaceuticals Israel Ltd., Herzliya Pituach, Israel

Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries

Completed

Conditions: Kidney Neoplasms

Interventions: Drug: sunitinib
Drug: axitinib

First Posted Date: 2020-12-16

Last Posted Date: 2024-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 1205

Registration Number: NCT04669366

Locations: 🇸🇪
Pfizer Innovations AB, Sollentuna, Sweden

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy